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Abstract
Background: Showing	how	engagement	adds	value	for	all	stakeholders	can	be	an	ef-
fective	motivator	for	broader	implementation	of	patient	engagement.	However,	it	is	
unclear	what	methods	can	best	be	used	to	evaluate	patient	engagement.	This	paper	
is	focused	on	ways	to	evaluate	patient	engagement	at	three	decision-making	points	
in	the	medicines	research	and	development	process:	research	priority	setting,	clinical	
trial	design	and	early	dialogues	with	 regulators	and	health	 technology	assessment	
bodies.
Objective: Our	aim	was	to	review	the	literature	on	monitoring	and	evaluation	of	pa-
tient	engagement,	with	a	focus	on	indicators	and	methods.
Search strategy and inclusion criteria: We	 undertook	 a	 scoping	 literature	 review	
using	 a	 systematic	 search,	 including	 academic	 and	 grey	 literature	with	 a	 focus	 on	
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1  | INTRODUC TION
There	is	increasing	consensus	among	stakeholders	that	patient	en-
gagement	in	research	and	development	(R&D)	of	medicines	provides	
benefits	for	patients,	researchers,	industry,	regulatory	bodies,	pay-
ers	and	policy	makers.1-3	The	case	for	patient	engagement	is	often	
presented	in	ethical	and	political	terms	referring	to	fairness,	trans-
parency	 and	accountability.4,5	Methodological	 arguments	 consider	
the	experiential	knowledge	of	patients—acquired	by	their	personal	
experience	of	a	condition—as	valuable	to	improving	the	quality	and	
relevance	 of	 the	 research.6-8	 The	 inclusion	 of	 patients	 in	 decision	
making	about	the	development	of	new	innovative	medicines	is	a	sub-
stantial	change,	requiring	time	and	(financial)	commitments	from	re-
searchers,	industry	and	patients.2,4	Despite	efforts	to	promote	and	
support	patient	engagement	in	research,	the	prevalence	of	patient	
engagement	in	medicines	research	and	development	remains	low.9,10 
Patient	engagement	has	not	been	fully	embedded	in	the	health	re-
search	system,	partly	because	it	is	not	yet	clear	to	all	involved	what	
the	added	value	is.11	To	address	this	need,	an	increasing	number	of	
studies	 aim	 to	evaluate	 the	 impact	of	patient	 engagement,	 under-
scoring	the	growing	interest	in	the	“return	on	engagement,”	or	why	it	
makes	sense	for	patients,	society	and	industry.2,12
The	perceived	value	of	patient	engagement	practices	can	vary	
for	 different	 stakeholder	 groups,	 and	 the	metrics	 of	 interest	will	
therefore	 differ	 accordingly.13	 For	 example,	 for	 researchers	 and	
industry	 partners	 it	 might	 be	 about	 evidence	 that	 patient	 en-
gagement	improves	the	quality	and	efficiency	of	research	and	the	
uptake	of	 findings,	whilst	 for	patients	 it	might	be	more	about	 in-
fluencing	the	R&D	agenda	to	develop	medicines	for	unmet	needs.	
Some	argue	that	evidence	 is	needed	to	 justify	the	 ‘business	case’	
for	engagement.	This	could	also	help	to	establish	a	financial	model	
to	 support	 engagement.2,14,15	 Evaluation	 could	 also	 define	 the	
genuine	 value	 of	 patients’	 contributions,	 contributing	 to	 valued	
rather	 than	 tokenistic	 inclusion	 for	 appearances’	 sake.16	 There	 is	
also	some	resistance;	people	are	concerned	about	assessing	impact	
too	simplistically.	Some	question	whether	it	is	fair	to	evaluate	the	
value	of	patient	 input	 in	 isolation,	and	not	 that	of	others	such	as	
key	scientific	leaders,12	not	least	because	it	may	be	the	synergy	of	
working	 in	partnership	 that	produces	benefit.17	As	mentioned	by	
Staniszewska,	 it	 is	 important	to	recognize	that	“any	form	of	mea-
surement	sits	within	a	political	or	 ideological	context	that	cannot	
be	ignored.”13	Nonetheless,	there	is	a	desire	to	assess	the	impact	of	
patient	engagement,	to	demonstrate	better	decision	making,	avoid-
ance	of	previous	errors	and	a	contribution	to	continuous	efficiency	
and	quality	improvement.15,16,18
Despite	this	perceived	importance	of	assessing	the	return	on	pa-
tient	engagement,	little	is	known	about	“what”	to	evaluate,	and	even	
less	about	“how.”19-21	A	number	of	researchers	have	tried	to	assess	
how	 patient	 engagement	 makes	 a	 difference.3,5,8,12,22-27	 Although	
there	 is	 no	 standardized	way	 to	 assess	 the	 impact	 of	 patient	 en-
gagement,	very	similar	benefits,	costs	and	challenges	are	reported	in	
literature	reviews.4,17,19,20,28-32	The	current	assessment	of	patient	en-
gagement	is	considered	weak,	partly	because	much	of	the	evidence	
is	mainly	anecdotal17	and	because	methods	used	have	not	captured	
the	complexity,	context	or	mechanisms	of	change.17,33	Previous	stud-
ies	have	identified	a	number	of	gaps	in	the	literature	and	identified	
challenges	such	as	the	delayed	nature	of	impact,	inconsistent	termi-
nology,	absence	of	accepted	criteria	for	judging	the	success	or	qual-
ity	of	research,	no	agreed	evaluation	methods	or	framework	and	few	
reliable	measurement	tools.	The	absence	of	a	control	group—identi-
cal	research	carried	out	without	patient	engagement—is	problematic	
too,	 particularly	 in	 an	 area	of	 science	where	direct	 comparison	 to	
evaluation	 approaches	 or	 outcomes	 associated	with	 patient	 engagement.	No	 date	
limits	were	applied	other	than	a	cut-off	of	publications	after	July	2018.
Data extraction and synthesis: Data	were	extracted	from	91	publications,	coded	and	
thematically	analysed.
Main results: A	total	of	18	benefits	and	5	costs	of	patient	engagement	were	identi-
fied,	mapped	with	28	possible	indicators	for	their	evaluation.	Several	quantitative	and	
qualitative	methods	were	found	for	the	evaluation	of	benefits	and	costs	of	patient	
engagement.
Discussion and conclusions: Currently	available	indicators	and	methods	are	of	some	
use	in	measuring	impact	but	are	not	sufficient	to	understand	the	pathway	to	impact,	
nor	whether	interaction	between	researchers	and	patients	leads	to	change.	We	sug-
gest	that	the	impacts	of	patient	engagement	can	best	be	determined	not	by	applying	
single	indicators,	but	a	coherent	set	of	measures.
K E Y W O R D S
evaluation,	framework,	impact,	literature	review,	medicines	development,	metrics,	patient	and	
public	involvement,	patient	engagement,	patient	participation,	research
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an	existing	standard	is	routinely	demanded.8,16,34,35	It	is	argued	that	
to	build	an	evidence	base,	some	level	of	consensus	on	measurable	
impacts	is	needed,	whilst	others	state	that	the	outcomes	of	engage-
ment	cannot	easily	be	quantified.13,30,36	 In	sum,	 it	 remains	unclear	
what	methods	can	be	best	used	to	evaluate	patient	engagement.
To	address	the	need	for	means	of	determining	the	“return	on	en-
gagement,”	the	aim	of	this	paper	was	to	scope,	review	and	summarize	
the	literature	on	monitoring	and	evaluation	of	patient	engagement.	
Many	publications	present	 useful	 guidance	 for	 conducting	patient	
engagement	and	assessing	the	quality.37-39	Evaluation	studies	focus	
mainly	on	qualitative	methods	and	only	occasionally	link	to	specific	
outcomes.12,33,40,41	Therefore,	this	paper	is	focused	on	ways	to	eval-
uate	patient	engagement	with	both	qualitative	and	explicitly	quan-
titative	methods.
This	 work	 is	 part	 of	 the	 PARADIGM	 project,	 a	 public-private	
partnership	that	 is	developing	ways	to	ensure	that	patients	are	al-
ways	meaningfully	 involved	 in	 the	development	of	medicines.	The	
impact	of	patient	engagement	may	differ	at	different	points	 in	the	
TA B L E  1  Definitions
Concept Description
Patient	
engagement
The	effective	and	active	collaboration	of	patients,	patient	advocates,	patient	representatives	and/or	carers	in	the	processes	
and	decisions	within	the	medicines	lifecycle,	along	with	all	other	relevant	stakeholders	when	appropriate1
Patient	partner A	patient,	patient	advocate,	patient	representative	and/or	carer	who	contributes	to	any	level	of	patient	engagement	activi-
ties;	this	can	also	be	substituted	for	other	terms	such	as	patient	contributor82
Research	
participant
A	person	who	participates	in	human	subject	research,	also	called	a	subject,	study	participant	or	volunteer	of	an	experiment	
or	trial
Society Includes	all	members	of	the	public	and	patients	who	use	health-care	services
Research	priority	
setting
Any	process	aimed	at	constructing	priorities	or	agendas	for	health	research	and	medicines	development,	to	raise	awareness	
and	change	the	way	research	funding	is	allocated
Design	of	clinical	
trials
Any	process	aimed	at	the	development	or	design	of	clinical	trials	for	medicines	development	at	any	stage	of	that	process.	
One	example	is	changes	made	to	inclusion	and	exclusion	criteria	for	trial	participants
Early	dialogues	
with	regula-
tors	and	Health	
Technology	
Assessment	
(HTA)	bodies
Any	process	in	which	medical	technology	developers	communicate	with	regulatory	bodies	and/or	HTA	bodies	prior	to	
health	technology	assessment.	Early	dialogue	can	happen	only	with	regulators	(eg	scientific	advice),	jointly	with	regulators	
and	HTA	bodies	(to	discuss	data	requirements	to	support	decision	making	on	marketing	authorization	and	reimbursement	
simultaneously)	or	only	with	HTA	bodies	(eg	EUnetHTA	multi-HTA	dialogues)
Benefit An	advantage	of	engagement	for	research	and	development	and	stakeholders	involved
Costs	and	
challenges
The	expenditure	and/or	effort	of	engagement	for	research	and	development	and	the	stakeholders	involved
Outcomes Decisions	made	and	things	produced	as	a	direct	result	of	patient	engagement	practices.	One	example	is	changes	made	in	the	
design	of	a	clinical	trial	resulting	in	a	more	relevant	and	appropriate	research	protocol.	Outcomes	may	lead	to	impact	on	
research	and	development
Impacts Broader	effect	of	outcomes,	both	positive	and	negative,	of	patient	engagement.	Impact	may	be	direct	or	indirect,	intended	
or	unintended.	For	example,	this	may	include	study	quality	benefits	such	as	improved	recruitment	and	retention	of	study	
participants
Value The	benefits	of	patient	engagement	(in	relation	to	the	direct	and	indirect	costs)	for	individuals	and	organizations	involved
Monitoring The	formative	evaluation	of	patient	engagement	practices	in	order	to	strengthen	them
Evaluation The	‘systematic	acquisition	and	assessment	of	information	to	provide	useful	feedback	about	…’	patient	engagement	
practices.83	Summative	evaluation	examines	the	effects	of	patient	engagement	practices	on	various	measures	including	
outcomes,	impact	and	cost-benefit
Criteria Dimensions	or	parameters	used	for	evaluation.	These	need	to	be	translated	into	measurable	entities	called	‘indicators’	and	
indicators	are	measured	with	‘metrics’
Indicator Qualitative	or	quantitative	measure	that	provides	a	means	of	expressing	achievement	of	a	goal	or	ascertaining	the	con-
sequences	of	a	specific	change.	Quantitative	indicators	are	reported	as	numbers,	such	as	rates	of	change	and	ratios.	
Qualitative	indicators	are	reported	as	words,	in	statements,	paragraphs	and	reports84
Metrics Observations	based	on	standardized	data	sources	or	agreed	techniques	for	gathering	information.	Metrics	could	consist	of	
an	agreed	set	of	quantitative	and/or	qualitative	indicators	to	measure	evaluation	criteria,	with	a	set	of	agreed	methods/
tools	to	collect	this	information
Methods Ways	to	collect	information	for	monitoring	and	evaluating	the	outcomes	and	impact	of	patient	engagement	practices,	for	
example	quantitative,	qualitative	or	mixed	methods
Tools Instruments	to	collect	information	about	patient	engagement	practices.	For	example,	interview	guides,	questionnaires,	log	
sheets	and	observation	forms	are	all	tools
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development	 of	 a	 medicine.	 Accordingly,	 PARADIGM	 focuses	 on	
three	decision-making	points	during	R&D	at	which	point	integration	
of	the	patient	perspective	is	considered	likely	to	be	valuable,	specif-
ically	as	part	of	research	priority	setting,	design	of	clinical	trials	and	
at	early	dialogues	with	regulators	and	health	technology	assessment	
bodies.	Each	of	these	represents	a	point	at	which	engagement	can	
influence	effective	planning	and	implementation,	and	demonstrate	
impact	on	the	final	product.
2  | METHODS
We	 undertook	 a	 scoping	 review	 of	 published	 academic	 and	 grey	
literature	 as	 recommended	 by	 Arksey	 and	O’Malley,	 also	 drawing	
on	Mays	 et	 al	 and	Peters	 et	 al42-44	 Scoping	 reviews	 are	 similar	 to	
systematic	reviews	in	that	they	follow	a	structured	search	process;	
however,	 they	are	performed	for	different	reasons.45	Our	aim	was	
not	to	answer	a	precise	question	addressing	the	effectiveness	of	a	
certain	practice,	as	 in	a	meta-analysis,	but	 to	provide	an	overview	
of	 the	 breadth	 of	 the	 available	 literature	 about	 evaluating	 patient	
engagement.
Whilst	the	review	is	concerned	with	patient	engagement	at	the	
three	key	decision-making	points,	we	used	broader	search	limits	to	
ensure	capture	of	 related	publications	 in	other	areas	of	health	 re-
search.	One	of	the	challenges	was	the	variety	of	terminology.	For	ex-
ample,	the	words	“measure,”	“metric”	and	“indicator”	are	often	used	
interchangeably	 and	 their	 definitions	may	 vary,	 if	 they	 are	 stated	
at	all.	Furthermore,	the	terms	used	for	“patient	engagement”	differ	
globally.	In	this	paper,	we	use	the	term	patient	engagement;	in	our	
search,	we	included	terms	such	as	public	 involvement,	patient	par-
ticipation,	community	engagement	and	user	involvement.	In	Table	1,	
we	provide	definitions	of	terms	developed	by	the	authors	and	as	we	
used	them	in	this	review.
2.1 | Search methods
Prior	to	the	database	search,	we	did	a	search	to	identify	a	tentative	
sample	set	of	relevant	studies	for	a	snowballing	exercise.	Using	broad	
key	words,	we	searched	Google	Scholar	 for	published	articles	and	
Google	for	grey	 literature.	We	also	searched	the	Patient-Centered	
Outcomes	Research	Institute	(PCORI)	database46	and	the	INVOLVE	
evidence library.47	A	snowballing	exercise	using	references	and	cita-
tions	from	these	articles	provided	a	starting	set	of	publications	that	
informed	the	protocol	for	the	main	review.	This	is	recommended	for	
the	 clarification	 of	 concepts	 and	 search	 terms	when	 interrogating	
large,	diverse	fields	of	literature.48
Accordingly,	 with	 the	 assistance	 of	 a	 specialist	 librarian,	 we	
searched	CINAHL,	Embase,	Medline,	PsychINFO	and	PubMed	da-
tabases	for	peer-reviewed	published	literature.	The	following	key	
words	 were	 used	 “patient	 engagement”	 combined	 with	 «	 AND»	
“research”	«	AND»	“outcomes,”	including	a	variation	of	terms	com-
bined	with	«	OR».	An	overview	of	all	search	terms	can	be	found	in	
Table	2.
Grey	literature	was	searched	using	the	same	terms;	items	rec-
ommended	 by	 consortium	 partners	 and	 external	 stakeholders	
were	added	manually,	and	reference	 lists	of	 items	 included	were	
searched	for	additional	publications.	All	searches	were	conducted	
between	1	May	2018	and	31	 July	2018.	The	 search	was	 limited	
to	publications	 in	English.	We	excluded	articles	that	did	not	pro-
vide	 information	on	possible	evaluation	approaches	or	outcomes	
associated	 with	 patient	 or	 public	 engagement.	 No	 date	 limits	
were	 applied	 other	 than	 a	 cut-off	 of	 publications	 after	 31	 July	
2018.	Following	completion	of	the	search,	duplicated	items	were	
removed.
2.2 | Study selection and data extraction
Two	researchers	(TF,	LV)	independently	screened	all	items’	title	and	
abstract.	To	ensure	inter-rater	reliability,	items	were	marked	for	in-
clusion	 or	 exclusion	 with	 each	 researcher's	 initials,	 discrepancies	
were	 discussed	 and	 consensus	 reached.	 Both	 researchers	 read	 all	
the	selected	items	in	full	and	followed	up	references	for	final	inclu-
sion.	At	this	stage,	further	exclusions	were	made	of	 items	that	did	
not	include	methods	for	evaluating	outcomes	and/or	impact	of	pa-
tient	engagement	practices	in	health	research	or	health	technology	
assessment—discrepancies	 were	 discussed,	 and	 consensus	 agreed	
for	final	inclusion	in	the	data	extraction	and	analysis.	Figure	1	dem-
onstrates	the	number	of	articles	identified,	screened,	selected	and	
reviewed.
TF	and	LV	developed	a	data	extraction	sheet	to	record	relevant	
information	 from	 each	 item,	 including	 the	 publication	 year	 and	
focus,	country	of	origin,	methodology,	patients	 involved	as	part-
ners,	use	of	a	framework	or	model,	definitions	included,	outcome	
and/or	 impact	 on	 research,	 benefits	 and	 costs	 per	 stakeholder	
group,	measurement	or	evaluation	methods	suggested	or	applied.	
TA B L E  2  Search	terms
Patient engagement  
(title only)
Research  
(title only)
Outcomes  
(title/abstract only)
Patient	participation	
[MeSH]
Comparative	
effective-
ness	research	
[MeSH]
Outcome(s)
Impact
Patient	engagement Research Measurement(s)
Public	engagement Clinical	trial Metrics
Client	engagement Study	design Framework(s)
Community	engagement Trial	design Assessment
Public	participation Research	design Criteria
Patient	participation Health	
technology	
assessment
Indicator(s)
Public	involvement Agenda	setting  
User	involvement   
Client	involvement   
Consumer	involvement   
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When	available,	context	and	process	criteria	were	also	 included.	
Both	researchers	extracted	data	 independently	from	30%	of	the	
scientific	 articles	 and	 then	 compared	 their	 findings	 to	 agree	 the	
approach	 to	 data	 extraction.	 Thereafter,	 all	 the	 peer-reviewed	
published	papers’	data	were	extracted	by	LV	and	the	grey	 litera-
ture	by	TF	and	LV.
2.3 | Analysis
Data	were	 thematically	 analysed	 following	Braun	 and	Clarke's	 ap-
proach.49	To	achieve	the	summary,	we	coded	data	using	the	review	
question,	aim	and	objective	as	included	on	the	data	extraction	sheet.	
Codes	used	were	benefits	(B),	costs	and	challenges	(C),	outcome	or	
impact	on	research	(O	or	I)	and	types	of	benefits	or	costs	and	chal-
lenges.	Codes	were	then	clustered	into	themes,	which	were	agreed	
by	TF	and	LV;	themes	were	identified	deductively	and	include	bene-
fits,	costs	and	challenges	for	each	stakeholder	group,	benefits,	costs	
and	 challenges	 for	 research	 per	 decision-making	 point,	 indicators,	
methods	or	tools.	LV	and	NG	clustered	the	indicators,	methods	and	
tools	into	qualitative	and	quantitative	types.	Benefits	and	costs	were	
mapped	to	suggested	or	applied	indicators	and	tools	or	methods.	The	
decision-making	 point	 focus	 of	 articles	was	 interpreted	 by	 the	 re-
searchers	if	not	defined	in	the	article.	Benefits	and	costs	that	could	
not	 easily	 be	 linked	 to	 one	 particular	 decision-making	 point	 were	
analysed	separately.	LV	and	TF	agreed	on	the	data	analysis	strategy,	
and	sections	of	the	analysis	were	cross-checked	by	comparing	inter-
pretations	of	results;	inconsistencies	were	discussed	and	agreed.
2.4 | Consultation and validation
The	preliminary	results	of	the	review	were	presented	and	discussed	
during	 a	PARADIGM	meeting	held	 in	 London,	18	 July	2018.	This	
session	provided	valuable	input	on	how	best	to	present	and	catego-
rize	 the	 results.	 Participants	 in	 the	meeting	 included	 representa-
tives	 from	 patient	 organizations,	 pharmaceutical	 companies	 and	
academia	 with	 an	 interest	 and	 considerable	 expertise	 in	 patient	
engagement.	Based	on	the	discussions	during	the	meeting,	 it	was	
agreed	to	structure	the	results	per	key	decision-making	point	and	
per	stakeholder,	including	benefits	and	costs.	These	members	of	the	
PARADIGM	consortium	were	involved	in	writing	this	article;	their	
interpretation	 of	 results	 informed	 the	 discussion	 and	 conclusion.	
Furthermore,	their	contributions	to	the	entire	research	process	in-
formed	the	direction	of	 research,	 the	terminology	and	definitions	
used	in	this	article.
3  | RESULTS
A	total	of	91	documents	met	the	eligibility	criteria	(academic	litera-
ture	n	=	77	and	grey	 literature	n	=	14).	 Included	documents	were	
published	between	2000	and	2018	and	focused	mainly	on	the	health	
research	field.	We	found	limited	documents	in	the	field	of	regulation	
and	health	technology	assessment.	Most	documents	were	published	
in	 the	 United	 Kingdom	 in	 an	 academic	 setting.	We	 found	 largely	
qualitative	studies	and	literature	reviews.	Sixteen	studies	reported	
F I G U R E  1  Article	selection	PRISMA	flow	diagram
Records from databases aer 
duplicates removed 
(n = 1305)
Records from grey literature and hand 
searching aer duplicates removed 
(n = 47)
Records included for full text reading 
(n = 168)
Records excluded aer full text reading:
• No informa on on possible evalua on 
approaches or outcomes
• No methods for evalua ng outcomes 
and impacts of pa ent engagement 
prac ces in health research or health 
technology assessment 
(n = 77) 
Iden fica on
Screening
Eligibility
Included Items included for data extrac on 
(n = 91)
Records included for Ti/Ab screening 
(n = 1352)
Records excluded aer screening Ti/Ab:
• Not wrien in English 
• Not about evalua on of pa ent 
engagement
(n = 1184)
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that	patients	were	involved	in	the	study	as	partners.	Table	3	provides	
an	overview	of	the	characteristics	of	included	documents.
In	this	section,	we	present	the	findings	of	our	review,	first	con-
sidering	 the	 three	 decision-making	 points,	 which	 were	 relevant	
to	our	 search.	Not	 all	 reported	benefits	 and	 costs	 could	 easily	 be	
linked	to	one	decision-making	point.	These	referred	to	overall	ben-
efits	and	costs	for	stakeholders	and	general	costs	or	challenges	for	
research	and	development.	Therefore,	we	 report	 them	separately.
Additionally,	reported	benefits	and	costs	were	omitted	where	they	
related	to	other	phases	of	the	research	process	(such	as	interpreta-
tion	of	research	findings	or	dissemination	of	results).
3.1 | Benefits, costs and challenges for research and 
development
A	total	of	18	benefits	and	five	costs	of	patient	engagement	at	three	
R&D	decision-making	points	were	 identified.	These	were	grouped	
into	11	domains	 and	mapped	with	28	possible	 indicators	 for	 their	
evaluation.	Tables	4	 and	5	provides	 an	overview	of	 indicators	per	
domain.	Please	refer	to	Appendices	S3–S5	for	more	detailed	indica-
tors,	evaluation	methods	and	tools.
3.1.1 | Benefits of patient engagement in research 
priority setting
Literature	 suggests	 that	 patient	 engagement	 in	 research	 priority	
setting	 has	 several	 benefits.	 We	 identified	 four	 unique	 benefits	
and	nine	possible	 indicators.	We	clustered	 the	benefits	 into	 three	
domains:	usability	benefits,	societal	benefits	and	funding	benefits.	
Usability	benefits	 refer	 to	 impact	on	the	topic	generation	and	pri-
oritization	process,	for	example	more	relevant	topics	and	priorities	
based	on	patients’	needs3,4,15,17,20,22,23,29,30,50-55	and	the	relevance	of	
studies,	for	example	more	relevant	research	questions	and	medical	
interventions	or	 technologies.30	Societal	benefits	 refer	 to	 the	way	
public	and	private	resources	are	allocated,	for	example	more	appro-
priate	resource	allocation	based	on	patients’	needs.30	Funding	ben-
efits	 refer	 to	new	 funding	and	 funding	opportunities,	 for	example	
success	 in	gaining	 funding	due	to	enhanced	credibility	of	 research	
proposals.25,29-32,56-58
In	the	 literature,	quantitative	methods	are	used	to	collect	 infor-
mation	about	 the	perceived	 importance	of	 studies	by	patients,	 the	
perceived	influence	of	stakeholders	in	research	priority	setting,23,59 
or	 to	 compare	 academic	 and	 lay	 scores	 assigned	 to	 research	 pro-
posal	 evaluation.60	 For	 example,	 studies	 suggest	 rating	 the	 impor-
tance	or	influence	of	partners	in	developing	the	research	topics.23,59 
Qualitative	methods	are	used	 to	explore	 the	 relevance	of	 research	
topics	and	how	patients’	experiential	knowledge	helped	shape	the	re-
search	question.30	The	Patient-Centered	Outcome	Institute	(PCORI)	
uses	mixed	methods	 (survey,	 focus	groups,	database	review)	 to	ex-
plore	the	perceptions	 incorporated	 into	the	topic	selection	process	
and	 the	 kinds	 of	 research	 gaps	 documented	 as	 important	 to	 pa-
tients	and	other	stakeholders	that	were	not	previously	 identified.61 
Quantitative	methods	could	also	be	used	for	comparison	of	academic	
and	lay	scores	assigned	to	research	proposals.60	Qualitative	methods	
are	 suggested	 for	 exploring	 similarities	 and	differences	 in	 research	
priorities.15	For	example,	Brown	et	al	invited	patients	with	diabetes	
to	focus	groups	to	identify	research	priorities.	Results	were	analysed	
using	the	constant	comparative	method	and	compared	with	current	
expert-led	 research	 priorities	 in	 diabetes.62	 Additionally,	 documen-
tary	analyses	(eg	review	of	minutes,	grant	applications,	reports)	may	
be	 conducted	 to	 compare	 patient	 input	 and	 responsiveness	 to	 pa-
tients’	ideas.54,61,63
3.1.2 | Benefits of patient engagement in the 
design of clinical trials
We	 identified	 ten	 unique	 benefits	 of	 patient	 engagement	 for	 the	
design	 of	 clinical	 trials,	 including	 13	 possible	 indicators.	We	 clus-
tered	 the	 benefits	 into	 three	 domains:	 ethical	 benefits,	 meth-
odological	 benefits	 and	 study	 quality	 benefits.	 Several	 studies	
described	 ethical	 benefits	 such	 as	 a	 more	 appropriate,	 inclu-
sive	 and	 sensitive	 research	 design.8,17,29,30,52,55,58	 Furthermore,	
TA B L E  3  Overview	of	characteristics	of	included	documents
Characteristic Output
Year Last	8	y	(2010-2018)	(n	=	69)
10	y	(2000-2010)	(n	=	22)
Focus Clinical	trial	(n	=	24)
Health	research	(n	=	47)
Regulation	and	HTA	(n	=	8)
Other	(n	=	12)
Country	of	origin Canada	(n	=	11)
United	Kingdom	(n	=	40)
Canada	and	the	United	Kingdom	(n	=	1)
United	States	(n	=	27)
Europe	(n	=	6)
Netherlands	(n	=	4)
Germany	(n	=	1)
Denmark	(n	=	1)
Setting Academia	(n	=	38)
Health	care	(n	=	19)
Industry	(n	=	3)
Mixed	(n	=	14)
Other	(n	=	17)
Methodology	(academic	
literature	only)
Quantitative	study	(n	=	6)
Qualitative	study	(n	=	23)
Mixed	method	study	(n	=	15)
Literature	review	(n	=	25)
Commentary/Editorial/Opinion/other	
(n	=	8)
Patients	involved	as	
partners	in	the	study	
(academic	literature	
only)
Yes	(n	=	16)
Unspecified	(n	=	61)
     |  7VAT eT Al.
studies	 described	 methodological	 benefits	 such	 as	 more	 appro-
priate	 wording	 and	 timing	 of	 research	 instruments	 and	 interven-
tions,17,20,22,24,25,27,29,31,55,56,64-68	 and	 improved	 consent	 forms	 and	
accessible	recruitment	materials.4,20,24,25,29,31,40,55,56,67,68	Study	qual-
ity	 benefits	 are	 also	 reported,	 for	 example	 improved	 trial	 recruit-
ment	and	retention.23,24,29,40,69
TA B L E  4  Summary	of	benefits	for	research	and	development	mapped	with	reported	indicators	for	evaluation
Research priority setting
Usability benefits (1) Examples of indicators related to usability benefits (total: 6)
More	relevant	research	topics	and	priorities,	based	
on	patients’	needs3,4,15,17,20,22,23,29,30,50-55
Rating	of	influence	of	patients	and	other	stakeholders61
Rating	of	relevance	or	importance	of	studies23,59
Perceptions	or	degree	of	contentment/satisfaction	with	the	topic	generation	and	prioriti-
zation	process96
Similarities	and	differences	in	research	priorities	between	stakeholder	groups15
Types	of	research	gaps	reported	that	were	not	previously	identified61
Perceptions	on	how	patients’	experiential	knowledge	helped	shaped	the	research	
question30
Research	questions,	hypothesis,	interventions	and	
medical	technologies	become	more	relevant	and	
usable	for	patients24,30
Societal benefits (2) Examples of indicators related to societal benefits (total: 3)
More	appropriate	resource	allocation,	based	on	
patients’	needs30
Comparison	of	academic	and	lay	scores	assigned	to	research	proposals60
Perceptions	of	public	influence	on	funding	decisions60
Indicators	of	dynamics	in	the	panel	discussion61
Funding benefits (3) Examples of indicators related to funding benefits (total: 1)
Improved	fundability	and	credibility	of	research	
proposals25,29-32,56-58
Number	of	studies	that	had	success	in	gaining	research	funding12
Design of clinical trials
Ethical benefits (4) Examples of indicators related to ethical benefits (total: 1)
More	appropriate,	inclusive	and	sensitive	research	
design8,17,29,30,52,55,58
Number	of	studies	that	had	success	in	gaining	ethics	approval12
Methodological benefits (5) Examples of indicators related to methodological benefits (total: 4)
More	appropriate	wording	and	tim-
ing	of	research	instruments	and	
interventions17,20,22,24,25,27,29,31,55,56,64-68
Number	of	changes	made	to	clinical	trial	communication	as	a	result	of	study	participant	
feedback59
Increased	readability	and	accessibility	of	research	
materials4,20,24,25,29,31,40,55,56,67,68
Reading	level	of	research	documents/instruments70
Rating	or	perceptions	of	understanding	of	the	consent	form70
More	relevant	research	outcomes/endpoints32,41,93 Number	and	type	of	patient-reported	outcomes61
Study quality benefits (6) Examples of indicators related to study quality benefits (total: 7)
Improved	recruitment	and	retention23,24,29,40,69 Recruitment	rates40,69,70
Number	of	study	participants	who	dropout	for	reasons	other	than	adverse	reactions59
Increased	diversity	of	study	participants66 Recruitment	and	retention	rates	among	hard-to-reach	population,	level	of	diversity61
Improved	trial	experience/satisfaction	by	study	
participants2,80
Rating	or	explore	feelings	of	satisfaction	among	study	participants15,70
Rating	convenience	of	study	visits	and	procedures	by	study	participants59
More	adherence	to	the	research	protocol93 Number	of	protocol	amendments59
Faster	study	completion2,23 Number	of	studies	completed	within	a	particular	timeframe3,61
Regulatory and HTA processes
Instrumental benefits (7) Examples of indicators related to instrumental benefits (total: 1)
Higher	accuracy	in	measuring	needs	and	preferences	
of	patients71,72
Perceptions	on	how	patient	input	was	used	and	added	value	for	assessment75,76
Better	quality	of	assessment	(in	terms	of	relevance	
and	reliability	to	local	context)71,72
 
Study uptake benefits (8) Examples of indicators related to study uptake benefits (total: 2)
Uptake	of	evidence/approval	by	regulators	and	HTA	
bodies2,73
Time	to	approval/response	of	regulators52
Changes	in	the	proportion	of	drugs	recommended	for	reimbursement36
Developmental benefits (9) Examples of indicators related to developmental benefits
Knowledge	and	public	awareness	of	products72 None	reported
Democratic	accountability	and	transparency72  
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The	 literature	 suggests	 several	 indicators	 and	 methods	 for	
the	 evaluation	 of	 patient	 engagement	 in	 the	 design	 of	 clinical	
trials.	For	example,	Guarino	et	al	measured	participants’	under-
standing	of	the	study	consent	form,	using	the	Informed	Consent	
Questionnaire-4	 questionnaire.	 The	 reading	 levels	 of	 the	 con-
sent	 forms	 were	 assessed	 using	 Flesch-Kincaid	 reading	 level	
scores.70	Rating	the	impact	of	patient	engagement	on	study	vol-
unteer	 attitudes	 about	 aspects	 of	 the	 participation	 process	 (eg	
ease	of	understanding	the	 informed	consent	form;	convenience	
of	study	visits	and	procedures)	 is	also	suggested.59	Other	stud-
ies	 suggest	 collecting	 data	 on	 the	 number	 of	 studies	 that	 gain	
research	 ethics	 committee	 approval,12	 the	 number	 of	 protocol	
amendments59	 and	 the	 number	 and	 type	 of	 patient-reported	
outcomes.61	 Furthermore,	 several	 studies	 have	 assessed	 study	
quality	 benefits,	 for	 example	 recruitment	 rates,	 using	 differ-
ent	 quantitative	 methods.40,69,70	 Iliffe,	 McGrath	 and	Mitchell40 
compared	 recruitment	 levels	 before	 and	 after	 the	 involvement	
of	the	public.	Guarino	et	al70	also	conducted	a	comparison;	they	
assessed	 the	effect	of	 two	different	 consent	documents	on	 re-
cruitment	 levels	 using	 one	 consent	 form	 developed	 by	 a	 con-
sumer	 focus	 group	 compared	 with	 another	 developed	 by	 the	
study	 investigators.	 Ennis	 and	Wykes	 conducted	 a	 quantitative	
analysis	of	 successful	 recruitment	by	studies	where	patient	en-
gagement	was	undertaken.	A	change	in	patient	engagement	over	
time	was	assessed	by	correlating	study	entry	order	(studies	were	
ordered	by	the	date	identified)	with	the	level	of	patient	engage-
ment.	Additionally,	suggested	indicators	include	recruitment	and	
retention	 rates	among	hard-to-reach	populations,61	 the	number	
of	dropouts	 for	 reasons	other	 than	adverse	 reactions,	 the	 total	
number	of	changes	made	to	clinical	trial	communications	as	a	re-
sult	of	patient	feedback,59	and	the	number	of	studies	completed	
within	a	particular	time	frame.3,61	Validated	questionnaires	such	
as	the	Client	Satisfaction	Questionnaire-8	measure	overall	satis-
faction	of	 study	participants.70	Qualitative	methods	 are	mostly	
suggested	 for	 gathering	 information	 about	participants’	 experi-
ences	of	taking	part	in	a	clinical	trial.15
3.1.3 | Benefits of patient engagement in regulatory 
processes and health technology assessment (HTA)
We	identified	five	unique	benefits	of	patient	engagement	in	regula-
tory	processes	and	HTA,	including	four	possible	indicators.	The	ben-
efits	can	be	categorized	into	three	dimensions:	instrumental	benefits,	
study	 uptake	 benefits	 and	 developmental	 benefits.	 Instrumental	
benefits	 are	 related	 to	 improving	 the	 relevance	 of	 assessment	 to	
making	 better	 quality	 decisions,	 for	 example	 higher	 accuracy	 in	
measuring	needs	and	preferences	of	patients	and	better	quality	of	
assessment	and	relevance	of	reports	to	the	local	context.71,72	Study	
uptake	benefits	refer	to	the	usefulness	of	assessments	for	decision	
makers	and	the	uptake	of	evidence	by	decision	makers,	for	example	
gaining	regulatory	approval.2,73	Developmental	benefits	include,	for	
example,	increasing	the	public's	understanding	of	HTA	and	openness	
of	decision	processes.72
Literature	 suggests	 a	 few	 methods	 to	 evaluate	 the	 bene-
fits	 of	 patient	 engagement	 in	 regulatory	 processes	 and	 HTA.	
Quantitative	methods	are	suggested	to	assess	study	uptake	ben-
efits	 such	 as	 the	 time	 to	 response/approval	 of	 regulators	 and	 a	
change	 in	 the	proportion	of	 drugs	 recommended	 for	 reimburse-
ment.3,74	Furthermore,	quantitative	methods	could	be	used	to	as-
sess	the	perceived	impact.	For	example,	the	European	Medicines	
Agency	 has	 used	 a	 survey	 to	 assess	 the	 perceived	 added	 value	
of	 patient	 input	 in	 scientific	 advice	 processes	 and	 feedback.75 
Qualitative	 methods	 can	 also	 be	 used	 to	 explore	 measures	 of	
change	or	uptake	of	patients’	 input.	For	example,	Abelson	et	al76 
assessed	how	patients’	 input	 informed	the	HTA	process	 through	
document	analysis,	 interviews	and	observations.	Dipankui	et	al77 
used	semi-structured	 interviews	and	document	analysis	 (eg	HTA	
reports,	 minutes)	 to	 evaluate	 how	 patient	 engagement	 changed	
the	HTA	report	and	its	recommendations.
3.2 | Costs and challenges of patient engagement in 
research and development
Limited	 studies	 have	 published	 costs	 and	 challenges.	 Of	 those	
which	have,	most	 studies	 reported	 increased	 time	and	costs	 for	
researchers	and	research	institutions	due	to	the	practical	aspects	
of	planning	and	managing	patient	engagement.	For	example,	there	
are	increased	time	and	financial	costs	from	building	relationships	
with	 the	relevant	community,	 setting	up	user	groups,	organizing	
and	providing	 training	 and	 education	 for	 users	 and	 researchers,	
and	 the	 additional	 time	 needed	 for	 users	 to	 read	 and	 comment	
on	 documentation.20	 Only	 two	 studies	 suggest	 that	 patient	 en-
gagement	 could	 potentially	 result	 in	 a	 more	 homogenous	 sam-
ple	 or	 biases	 in	 recruitment.24,67	 For	 example,	 Blackburn	 et	 al24 
reported	that	a	more	homogenous	study	sample	may	have	been	
recruited,	since	the	young	contributors	encouraged	their	friends	
to	participate	in	a	study	on	reproductive	health	in	young	people.	
Furthermore,	Brett	et	al	found	that	studies	indicated	that	patient	
engagement	 led	 to	 scientific	 and	ethical	 conflict	 in	protocol	de-
sign.	Also,	patient	engagement	may	lead	to	tokenistic	engagement	
TA B L E  5  Summary	of	costs	for	research	and	development	
mapped	with	reported	indicators	for	evaluation
Various decision‐making points
Non‐financial costs (10) Examples of indicators related to 
non‐financial costs (total: 2)
Biases	in	recruitment	or	
findings24,67
Perceived	negative	impacts	of	
patient	engagement	for	research	
and	development24
Total	hours	spent	on	engagement24
Scientific	and	ethical	conflict	
in	protocol	design20
Power	struggles20
Increased	time20
Financial costs (11) Examples of indicators related to 
financial costs (total: 1)
Increased	costs20 Total	monetary	costs	of	en-
gagement	for	research	and	
development24
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and	can	lead	to	power	struggles	between	researchers	and	patient	
partners.20	Furthermore,	stakeholders	have	raised	concerns	that	
engaged	 patients	 may	 want	 to	 see	 their	 clinical	 trials	 succeed,	
and	 as	 a	 result,	 these	 patients	may	 bias	 the	 study	 findings.59	 It	
was	also	reported	that	a	number	of	clinical	research	professionals	
fear	that	patient	centricity	is	pushing	them	to	discard	traditional	
practices,	 including	 the	 use	 of	 blinded,	 randomized	 controlled	
clinical	trials.59
Methods	to	assess	costs	 include	qualitative	methods	to	gather	
insights	into	the	perceived	effort	of	engagement	as	well	as	a	quan-
titative	method	to	gather	insights	into	financial	costs.	For	example,	
the	costs	and	consequences	framework	developed	by	Blackburn	et	
TA B L E  6  Summary	of	benefits,	costs	and	challenges	per	stakeholder	group
Individuals and 
organizations Benefits Costs and challenges
Patient	partners •	 Empowerment8,19,20,29-31,55,85,86
•	 Enhanced	well-being29,30,87
•	 Learning	about	research	and	gaining	research	and	
transferable	skills20,24,29,55,97
•	 Learning	about	own	condition	and	treatment	
options54,79
•	 Enjoyment	and	satisfaction22,29,55,87
•	 Supportive,	meaningful	relationships29,31,79
•	 Possible	remuneration8,54
•	 Future	prospects29,30,79,87
•	 Confusion	due	to	lack	of	clarity	about	roles	and	
procedures67,79
•	 Disappointment	and	frustration	due	to	mismatched	
expectations20,27
•	 Stress	due	to	lack	of	knowledge	and	confidence	and	a	
burden	of	responsibility24,79
• Overburdened5,29,55,79
•	 Investment	of	time	and	possibly	own	
resources4,24,67,79,88
•	 Possible	reduction	of	welfare	payments24
Society •	 Hope	and	trust	in	research/ers29,67,79
•	 Funding	and	prioritization	of	research	relevant	to	the	
community3
•	 Potentially	more,	relevant	drugs	recommended	for	
reimbursement74
•	 Increased	awareness	of	and	advocacy	for	condition	
and	associated	research67,79
•	 Uncover	or	create	conflict	and	power	struggles	in	the	
community79
•	 More	time	and	resources67,79,85
•	 Difficulty	representing	vulnerable/hard-to-reach	
groups67,79
Research	participants •	 Accessible	information	on	all	aspects	of	disease	and	
treatment24,55
•	 More	positive	experience	of	research	
participation2,55,80
 
Researchers •	 Learning	about	patients’	view	of	condition	and	
patient	engagement's	effects	on	research5,8,24,26,28-30
•	 Enhanced	knowledge	and	skills8,28,55,79
•	 Fresh	perspective	on	what	research	can	
achieve19,20,22,85
•	 Enjoyment	and	satisfaction29
•	 Career	benefits29,67
•	 Methodological	concerns	and	costs20,32,59
•	 Stress	due	to	new	ways	of	working	with	patients	
and	advocacy	groups	and	associated	power	
struggles4,20,32,55,67,79
•	 More	resource-intensive	research	
process19,55,67,79,86,87,89,90
Research	institutes •	 Increased	research	impact24
•	 Enhanced	reputation24
•	 Diversion	of	research	funds	to	patient	engagement	
(opportunity	cost	in	terms	of	funded	researcher	time,	
etc)24
•	 IT	and	other	support	infrastructures	24
Research	funders •	 More	relevant	funding	decisions24
•	 Increased	transparency	and	accountability55,67
•	 Possible	challenge	to	balance	scientific	integrity	and	
relevant	research55
Industry •	 More	cost-effective	R&D2,85,91-93
•	 More	regulatory	success2
•	 Enhanced	reputation2,31
•	 Better	patient	concordance	with	treatment93,94
•	 Enhanced	knowledge94
•	 More	resource-intensive	R&D20
Regulators	and	health	
technology	assessment	
bodies
•	 Better	understanding	of	real-life	context	of	
products71
•	 More	efficient,	relevant	regulatory	decisions95
•	 Increased	transparency	and	accountability73,74
•	 Mutual	respect	between	regulators	and	consumers73
•	 Increased	uncertainty	in	policy-making	due	to	varied	
views67
Others	(decision	mak-
ers	and	health-care	
providers)
•	 More	useful	evidence	for	clinical	and	health	policy	
decision	making30
•	 Uncertainty	about	how	to	take	the	study	recommen-
dations	forward	due	to	complexities	of	conflicting	
clinical	and	health	system	goals	between	clinicians,	
researchers,	and	users55
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al	includes	questions	about	costs	for	researchers	such	as	total	costs	
associated	with	recruiting	patients	involved,	the	total	costs	associ-
ated	with	training	patients	involved,	the	total	costs	associated	with	
supporting	 patients,	 financial	 payment/rewards,	 total	 costs	 of	 ex-
penses	 reimbursed	 to	 all	 patients	 for	 their	 involvement	 and	other	
costs	(including	parking	permits,	room	booking,	audio-visual,	equip-
ment).	 A	 separate	 questionnaire	 developed	 for	 patients	 includes	
questions	 about	 the	 hours	 spent	 on	 engagement,	 the	 costs	 they	
incurred	(eg	travel,	child	care,	food	and	drinks,	accommodation)	and	
any	costs	related	to	arrangement	and	planning	(for	instance	changed	
shifts	at	work	or	arranged	care	for	a	relative).24	Log	sheets	are	also	
used	 to	gather	 insights	 into	 time	and	costs.27	Open	questions	 are	
used	to	gather	insights	into	(non-financial)	negative	impacts.24
3.3 | Benefits, costs and challenges for stakeholders
Studies	 that	 assessed	 patient	 engagement	 for	 individuals	 and	 or-
ganizations	 mostly	 highlighted	 benefits,	 costs	 and	 challenges	 for	
patients	engaged,	with	comparatively	less	published	on	the	benefits	
and	costs	for	other	groups.	Based	on	our	review,	suggested	dimen-
sions	to	measure	the	benefits,	costs	and	challenges	for	the	individu-
als	and	organizations	involved	relate	to	personal	development,	skills	
and	 knowledge,	 emotions	 and	 meaningful	 relationships,	 financial,	
performance	and	strategic	value,	transparency	and	awareness,	trust	
and	mutual	respect.	A	summary	of	reported	benefits	and	costs	for	
stakeholders	can	be	found	in	Table	6.	Please	refer	to	Appendices	S1	
and	S2	 for	more	detailed	 information	on	benefits,	 costs	 and	chal-
lenges	for	patients	and	other	stakeholders.
Multiple	 tools	have	been	developed	 to	assess	 the	benefits	and	
costs	for	stakeholders.	The	Evaluation	Toolkit	is	a	resource	designed	
for	practitioners	of	the	health	sector,	produced	after	the	completion	
of	 a	 rigorous	 systematic	 review	of	 patient	 and	 public	 engagement	
evaluation	tools.78	Boivin	et	al	reviewed	the	tools	and	concluded	that	
most	tools	were	designed	to	collect	 information	from	patients	and	
the	public;	very	few	instruments	measure	the	perspectives	of	other	
stakeholder	groups.	The	authors	of	the	review	reported	that	the	out-
comes	of	patient	engagement	were	least	often	evaluated	(55.6%	of	
the	tools),	 in	contrast	to	the	engagement	process	and	context.	The	
most	 common	 focus	 of	 tools	 that	measure	 outcomes	was	 on	 per-
ceived,	self-reported	impacts.	Methods	are	qualitative	(eg	interviews,	
focus	groups)	and	quantitative	for	perceived	self-reported	benefits	
(eg	surveys	using	Likert	scales).	Self-administered	questionnaires	and	
surveys	were	the	most	common	types	of	tools	identified.21
4  | DISCUSSION
To	address	the	need	for	means	of	determining	the	“return	on	engage-
ment,”	the	aim	of	this	paper	was	to	review	the	literature	on	monitor-
ing	and	evaluation	of	patient	engagement.	This	review	identified	a	
range	of	benefits,	costs	and	challenges	that	patient	engagement	can	
have	on	R&D	and	describes	several	indicators	associated	with	their	
monitoring	and	evaluation.	 In	addition,	we	summarized	the	overall	
reported	benefits,	costs	and	challenges	for	stakeholders	involved	in	
patient	engagement	initiatives.	In	this	section,	we	reflect	on	the	in-
dicators	and	methods	found	in	this	review	and	consider	the	review's	
methodological	strengths	and	limitations.
4.1 | Reflection on our findings
A	total	of	18	benefits	and	five	costs	of	patient	engagement	at	the	
three	decision-making	points	were	 identified	 in	 this	 review.	These	
were	grouped	into	11	domains	and	mapped	with	28	possible	indica-
tors	for	their	evaluation.	Little	is	known	about	the	validity	and	per-
formance	of	 these	 indicators	 as	most	were	 suggested	 rather	 than	
applied,	or	used	in	single	studies.	Those	studies	mostly	considered	
a	single	indicator	(eg	recruitment	rate)	for	trying	to	answer	a	single	
question	 (eg	 Does	 patient	 engagement	 in	 research	 lead	 to	 better	
recruitment?).	Measuring	this	may	be	feasible	but	may	not	be	use-
ful	in	predicting	impact	for	other	studies,	as	the	factors	influencing	
impact	may	differ.	This	has	been	noted	by	other	authors.36	We	argue	
that	currently	available	indicators	are	of	some	use	in	measuring	ben-
efits,	but	are	not	sufficient	to	understand	the	pathway	to	impact,	or	
whether	the	interaction	between	researchers	and	patients	involved	
could	lead	to	change	in	the	external	environment	(eg	research	cul-
ture,	structure	and	practice).	We	argue	that	the	impacts	of	patient	
engagement	can	best	be	determined	not	by	applying	a	single	indica-
tor,	but	a	coherent	set	of	measures.	Given	the	 importance	of	con-
text	and	the	complexity	of	evaluating	patient	engagement	that	this	
review	 illustrates,	we	 are	 developing	 a	monitoring	 and	 evaluation	
framework	that	considers	various	indicators	for	patient	engagement	
practices	in	medicines	research	and	development.	This	framework	is	
informed	by	other	frameworks	and	being	tested	in	practice.	We	will	
publish	our	findings	of	working	with	a	more	coherent	evaluation	ap-
proach	in	medicines	research	and	development	shortly.
This	review	also	looked	at	methods	for	evaluation.	We	identified	
several	quantitative	methods	to	measure	the	benefits	of	patient	en-
gagement;	these	mostly	assess	the	benefits	on	study	quality,	study	
uptake	and	 self-reported	benefits.	Qualitative	methods	are	mostly	
suggested	 for	 gathering	 information	 about	 experiences,	 attitudes	
and	perceptions.	We	agree	with	others	that	there	is	a	need	for	new	
evaluation	methods	and	tools	that	focus	on	observable	impact	on	the	
research	process	and	benefits	for	those	involved.4,21,79,80	Some	argue	
for	broadly	applicable,	quantitative	methods	whilst	others	contend	
that	more	subjective,	qualitative	methods	are	necessary	to	capture	
the	nuances	of	outcomes	and	impacts	of	patient	engagement.13,17,59,76 
Universally	applicable	evaluation	criteria	that	capture	all	aspects	of	
engagement	are	supported	for	reasons	of	consistency,	reliability	and	
comparison	 across	different	 projects.16	 To	build	 an	 evidence	base,	
conceptual	and	practical	guidance	and	some	 level	of	consensus	on	
measurable	 impacts	 are	 needed.	 This	 has	 also	 been	 suggested	 by	
other	 authors.13,30	 However,	 whilst	 a	 standardized	 approach	 may	
be	appealing	to	health	research	and	development	communities,	it	is	
problematic	 in	 the	 complex	 and	 contextually	 dependent	 arenas	 of	
patient	engagement.81	 It	might	 inhibit	capacity-building	 in	projects	
and	makes	changes	difficult;	arguably,	 this	undermines	the	original	
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rationale	 for	 patient	 engagement.	 The	 tension	 between	 obtaining	
comparable	data	on	patient	engagement	by	using	metrics	(standard-
ized	 or	 agreed	 techniques	 for	 gathering	 information)	 and	 tailored	
participatory	 evaluative	 approaches	 should	 not	 be	 overlooked.	 By	
implication,	it	should	be	recognized	that	measures	can	be	valued	and	
applied	differently	 in	different	contexts;	therefore,	we	recommend	
discussing	relevant	and	feasible	indicators	and	methods	per	setting.
4.2 | Strengths and limitations of this review
To	our	 knowledge,	 this	 is	 the	 first	 literature	 review	 that	 attempts	
to	capture	the	existing	publications	about	the	evaluation	of	patient	
engagement	practice	as	it	relates	to	medicines	development.	It	both	
maps	outcomes	and	impacts	of	patient	engagement	with	suggested	
measures	for	each	decision-making	point	in	R&D.
Very	few	publications	refer	to	costs	or	negative	 impact	of	en-
gagement,	 compared	with	positive	 findings.	This	may	be	because	
people	tend	not	to	report	negative	outcomes	and	impacts	despite	
their	being	just	as	important.	There	were	very	few	studies	that	con-
sidered	 patient	 engagement	 in	 the	 HTA	 process,	 and	 only,	 three	
publications	were	authored	by	(and	for)	the	pharmaceutical	indus-
try.	 Furthermore,	 of	 the	 papers	 included	 in	 our	 review,	 very	 few	
reported	that	they	had	involved	patients;	therefore,	the	conclusions	
derived	from	the	studies	may	be	based	on	the	perspectives	of	re-
searchers.	For	 this	 review,	a	meeting	was	held	 to	discuss	prelimi-
nary	findings	with	a	broad	range	of	stakeholders	in	our	project	and	
the	co-authors	of	this	paper	work	for	patient	representative	groups	
and	industry.	We	therefore	feel	that	our	findings	may	be	considered	
relevant	to	a	broader	audience	than	a	predominantly	academic	one.
Our	focus	on	the	measurement	of	impact	of	patient	engagement	
in	the	development	of	medicines	has	resulted	in	several	limitations	
to	our	review.	Because	this	 is	a	scoping	review	rather	than	a	sys-
tematic	 review,	we	may	have	missed	relevant	articles.	Our	search	
focused	on	titles	and	abstracts	of	publications	and	three	decision-
making	points,	which	means	that	some	articles	(eg	related	to	other	
time	points)	have	been	excluded.	We	specifically	searched	for	out-
comes	and	impact	of	patient	engagement	in	the	R&D	of	medicines;	
therefore,	our	paper	does	not	include	context	or	process	indicators,	
or	 the	 indicators	 per	 stakeholder	 group.	 Furthermore,	we	 cannot	
draw	hard	conclusions	about	the	relationship	between	 input,	out-
comes	and	 impact	with	 respect	 to	 the	benefits	 and	 costs	 for	 the	
people	and	organizations	 involved	 in	patient	engagement.	Finally,	
we	had	to	exclude	articles	not	published	in	English.	Whilst	we	are	
aware	 that	most	 publications	 on	 this	 topic	 are	written	 in	 English	
originating	from	the	UK	and	North	America,	we	acknowledge	that	
we	may	have	missed	relevant	publications	in	other	languages.
5  | CONCLUSIONS
For	 patient	 engagement	 in	 the	 development	 of	 medicines	 to	
become	 standard	 practice	 at	 the	 key	 decision-making	 points	
of	priority	 setting,	 clinical	 trial	 design	and	 regulatory	 and	HTA	
processes,	 benefits	 need	 to	 be	 demonstrable	 to	 all	 stakehold-
ers.	This	literature	review	has	mapped	benefits,	costs	and	chal-
lenges	with	 indicators	 in	 current	 literature.	Discrete	 tools	 and	
methods	for	evaluation	are	less	apparent,	as	is	evidence	of	their	
application.	The	approaches	to	evaluation	we	found	are	largely	
qualitative,	 and	 our	 review	 suggests	 that	 there	 are	 few	 quan-
titative	 tools	 and	no	 standardized	approaches	 to	assessing	 the	
outcomes	and	 impact.	The	reported	costs,	challenges	and	ben-
efits	are	largely	congruent,	with	agreement	that	there	is	a	need	
for	consensus-based	monitoring	and	evaluation	frameworks	that	
include	metrics.
We	suggest	that	the	development	of	a	coherent	set	of	measures	
warrants	further	investigation	and	that	the	benefits,	costs	and	chal-
lenges	of	patient	engagement	 for	all	 stakeholders	should	be	given	
more	 consideration	 (rather	 than	 the	 current	 focus	 on	 benefits	 for	
research).	 To	 this	 end,	 we	 will	 co-develop	 and	 test	 an	 evaluation	
framework	with	stakeholders	using	a	reflexive	monitoring	approach	
in	real-life	cases	of	patient	engagement	 in	medicines	research	and	
development.
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